Research Plan
In the first step of the research plan, quality indicators (QI) will be developed to measure whether safe care is ensured in outpatient chemotherapy nursing practice, life-threatening adverse events are actually prevented, and patient satisfaction and quality of life (QOL) are enhanced.In the second step, safe care mechanisms and modules will be developed to manage life-threatening adverse events and minimize risk, and their validity will be verified. In the third step, based on the plan-do-check-act (PDCA) model, a prototype of the quality assurance monitoring system for checking whether safe care is actually being practiced in the clinical scene will be designed, and standard profiles for the trial use of the system will be created.In the fourth step, multi-center randomized controlled studies will be conducted to compare the incidence of life-threatening adverse events, frequency of emergency hospitalization, treatment delay time, frequency of treatment discontinuation, treatment-related mortality, etc., between patients to whom the integrated quality assurance system (QI, care module for best practice, quality assurance monitoring system) has been applied (experiment group) and those receiving normal care (control group).
2016-2017
Investigation of the long-term morbidity and risk for chemotherapy-induced peripheral neurotoxicity and dermatological toxicities in cancer survivors
(1) Investigation of the status of chemotherapy-induced peripheral neurotoxicity and dermatological toxicities in cancer survivors and exploration of factors that are associated with these complications (a retrospective cohort study)
(2) Design and verification of a "Safe and Secure Cancer Care Network" based on the study results and literature review
In the current study, we aim to standardize the "Safe and Secure Cancer Care Network" for cancer survivors with chemotherapy-induced peripheral neurotoxicity and dermatological toxicities, which will be a linchpin for expanding cancer survivors' life opportunities, and to build a care network that would efficiently make such care accessible to cancer survivors who receive cancer care. In addition, we will study the effectiveness of the "Safe and Secure Cancer Care Network" at various institutions and regions in order to examine whether this service would lead to a reduction in health care costs and an increase in the labor force.
The current study will be conducted in a phased manner with the following 5 steps.
(1) Investigation of the status of chemotherapy-induced peripheral neurotoxicity and dermatological toxicities in cancer survivors and exploration of factors associated with these complications (a retrospective cohort study)
(2) Design and verification of the "Safe and Secure Cancer Care Network" based on the study results and literature review
(3) Evaluation of the effects of the "Safe and Secure Cancer Care Network" by a multi-institutional randomized controlled trial
(4) Examination of the economic effects of the "Safe and Secure Cancer Care Network" for the management of chemotherapy-induced peripheral neurotoxicity and dermatological toxicities in cancer survivors
(5) Building a care network to disseminate the "Safe and Secure Cancer Care Network" module in two regions − an urban area and a rural area − and examining its feasibility.
In Step 3, a mixed method approach will be used to perform a multifaceted evaluation that takes into consideration the perspectives of cancer survivors.
